Abstract
- Background
Irritable bowel syndrome (IBS) remains a highly prevalent and clinically challenging functional gastrointestinal condition characterized by chronic abdominal discomfort, altered bowel habits, and impaired patient quality of life. In response to the limitations of conventional pharmacological therapies, there is a growing clinical and scientific interest in the application of traditional botanical medicines. Curcumin, the primary biologically active phytochemical extracted from Curcuma longa (turmeric), has demonstrated potent anti-inflammatory, antioxidant, mucosal protective, and gut microbiota-modulating properties in preclinical experimental colitis models. This meta-analysis was designed to evaluate the clinical hypothesis that curcumin supplementation improves global IBS symptom severity scores and provides a safe therapeutic option for affected patients.
- Methods
A comprehensive systematic literature search was executed utilizing targeted keyword combinations—including (curcumin OR turmeric OR Indian saffron OR diferuloylmethane OR curcuminoid) AND (irritable bowel syndrome OR IBS)—across major scientific databases, specifically PubMed, Medline, Embase, PsychINFO, Web of Science, and Google Scholar. The initial search identified 1080 English-language publications spanning from January 1, 1988, to May 1, 2018. Following rigorous screening, five randomized controlled trials (RCTs) were systematically reviewed, of which three studies meeting all inclusion criteria were incorporated into the final quantitative meta-analysis. A random-effects meta-analysis model was applied to evaluate standardized mean differences (SMD) and 95% confidence intervals (CI) based on pooled patient cohorts. Evaluated endpoints encompassed baseline-to-post-intervention IBS severity rating changes, clinical safety, and treatment tolerability.
- Results
Quantitative meta-analytic synthesis of the included trials provided empirical insights into the therapeutic profile of curcumin in IBS management:
Symptom Improvement Trend: Random-effects meta-analysis based on three clinical trials comprising 326 patients demonstrated that curcumin administration exerted a beneficial, albeit statistically non-significant, reduction in overall IBS symptom severity scores compared to control groups (pooled standardized mean difference from baseline IBS severity rating = -0.466; 95% CI: -1.113 to 0.182; $P = 0.158$).
Mechanism & Therapeutic Potential: Despite statistical limitations in early trials, curcumin's unique antioxidant and anti-inflammatory activities, alongside its capacity to modulate gut microbiota composition, underscore its strong theoretical utility as an adjunctive agent for IBS.
Safety & Tolerability: Curcumin exhibited an exemplary safety and tolerability profile, with zero adverse events reported across the evaluated clinical trial cohorts.
Methodological Limitations: Current empirical findings are constrained by a limited preliminary evidence base and notable inter-study heterogeneity, emphasizing the necessity for larger, more standardized clinical investigations.
- Conclusions
While early meta-analytic findings indicate a beneficial, non-significant trend toward symptom reduction in irritable bowel syndrome following curcumin supplementation, current evidence is limited by small sample sizes and heterogeneity. Given its excellent safety profile, potent antioxidant properties, and ability to modulate gut microbiota, curcumin remains a promising therapeutic candidate. Future robust clinical trials utilizing standardized curcumin preparations and larger cohorts are strongly warranted to establish definitive clinical efficacy.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6210149/